Tasadenoturev

The oncolytic virus therapy landscape has expanded steadily over the past decade, with over 100 companies worldwide pursuing clinical or preclinical programs. A few leaders, such as Candel Therapeutics, Binhui Biopharmaceutical, Oncolytics Biotech, EpicentRx, Hangzhou Converd, and others, anchor the mid and late-stage pipeline. LAS VEGAS, Feb. 4, 2026 /PRNewswire/ -- DelveInsight's Oncolytic Virus Competitive Landscape 2026 report provides comprehensive global coverage of pipeline oncolytic virus therapies across various stages of clinical development. The report offers an in-depth analysis of key trends, emerging therapies, and the competitive landscape, highlighting the strategies of major pharmaceutical companies to advance their pipelines and capitalize on future growth opportunities. In addition, it provides critical insights into clinical trial benchmarking, partnering and licensing, and regulatory pathways with the FDA and EMA, enabling stakeholders to make informed decisions and optimize development strategies in the oncolytic virus domain. Oncolytic Virus Clinical Trial Analysis Summary DelveInsight's oncolytic virus pipeline report highlights a robust landscape, with 100+ active players developing 110+ oncolytic virus drugs. Key oncolytic virus companies such as Oncolytics Biotech, SillaJen, Candel Therapeutics, Binhui Biopharmaceutical, Oryx GmbH, Oncolys Biopharma, EpicentRx, Theriva Biologics, Lokon Pharma, DNAtrix, Surv BioPharma Inc., Treovir, Immvira Pharma, Virogin Biotech, OrienGene Biotechnology, Apices Soluciones, Vyriad, Transgene, BioEclipse Therapeutics, Imugene, CG Oncology, Istari Oncology, Akamis Bio, Elicera Therapeutics, and others are evaluating new oncolytic virus drugs to improve the treatment landscape. Promising pipeline oncolytic virus therapies, such as Pelareorep, Pexa-Vec, CAN-2409, BS001, ParvOryx, Telomelysin, AdAPT-001, VCN-01, LOAd 703, DNX-2401, Surv.m-CRA-1, G207, MVR-T3011, VG161, OrienX010, AloCelyvir, Voyager-V1, TG6002, CRX-100, CF33-hNIS, CG0070, PVS-RIPO, NG-350A, ELC-201, and others, are in different phases of oncolytic virus clinical trials. Request a sample and discover the recent advances in oncolytic virus drugs @ Key Factors Driving the Oncolytic Virus Therapy Market Growing Cancer Incidence: The global rise in cancer prevalence, especially in hard-to-treat solid tumors, has intensified demand for novel, effective treatment modalities. Conventional therapies such as chemotherapy and radiation often have significant side effects and limited long-term efficacy, motivating the adoption of immunotherapeutic alternatives like oncolytic virus therapies. Increasing Understanding of Cancer Biology: Growing knowledge of cancer biology has enabled the development of oncolytic virus therapies that selectively target and destroy cancer cells while sparing healthy cells. Advancements in Viral Engineering: These advances are enabling more precise, targeted oncolytic virus therapies, significantly expanding the global oncolytic virus therapy market. Rising Adoption of Personalized Medicine: Oncolytic virus therapies align closely with personalized treatment approaches by enabling tailored viral constructs and immunomodulatory payloads based on tumor genomics. What is Oncolytic Virus Therapy? Oncolytic virus therapy is an innovative form of cancer treatment that uses genetically engineered or naturally occurring viruses to selectively infect and destroy cancer cells. These viruses replicate inside tumor cells, causing them to burst while leaving healthy cells largely unharmed. As the cancer cells break apart, they release tumor antigens that help activate the body's immune system, enhancing its ability to recognize and attack remaining cancer cells. This dual action, direct tumor destruction and immune stimulation, makes oncolytic virus therapy a promising approach in modern oncology, often used alongside other treatments such as immunotherapy or chemotherapy. Applications of Oncolytic Virus Therapy Oncolytic virus (OV) cancer therapies can be used for both diagnosis and treatment of cancer. OVs can function as cancer vaccines by boosting tumor-specific T-cell responses. Oncolytic viruses can be engineered with immunostimulatory molecules to enhance immune activation. OVs show strong synergy when combined with other immunotherapies, such as checkpoint inhibitors. Oncolytic Viruses in Combination with Chemotherapy Chemotherapy works systemically, unlike surgical resection or radiotherapy. It remains essential for treating patients with disseminated (widespread) cancer. Because chemotherapy is systemic, it is often combined with oncolytic viruses (OVs), which typically require localized delivery to achieve a strong antitumor effect. Systemically administered OVs have shown limited therapeutic benefit in several clinical trials. Delivering OVs effectively to metastatic sites remains a major challenge. Therefore, using chemotherapy as a systemic adjuvant to localized OV therapy is of significant clinical interest and is currently being actively investigated. Oncolytic Virus Market Analysis: Drug Profile IMLYGIC: Amgen IMLYGIC (talimogene laherparepvec), developed by Amgen, is a first-of-its-kind oncolytic viral therapy for melanoma that cannot be surgically removed. It combines direct tumors destruction with immune system stimulation. The therapy is based on a genetically engineered herpesvirus engineered to preferentially infect and destroy cancer cells, releasing GM-CSF to trigger a broader anti-tumor immune response. In the Phase III OPTiM trial, IMLYGIC produced durable responses in about 16% of patients, compared with 2% with GM-CSF alone, and overall responses in roughly 26%. Patients at earlier disease stages achieved better outcomes, with some achieving long-term control. The treatment is usually well tolerated, with most adverse effects being mild and resembling flu symptoms. Although its independent effect on survival and deep organ metastases is modest, its value is most evident when combined with checkpoint inhibitors. Early data show response rates approaching 56%, and ongoing studies aim to further define these synergistic benefits. As the first FDA-approved oncolytic virus in the West, IMLYGIC has validated the broader concept of viral immunotherapy and is now being explored as a component of combination immuno-oncology approaches. Oncorine: Shanghai Sunway Biotech Oncorine, also known as H101, is a genetically engineered adenovirus with an E1B gene deletion developed by Shanghai Sunway Biotech in China. It is administered alongside chemotherapy to treat nasopharyngeal carcinoma and head and neck cancers. Its approval and effective clinical use have significantly advanced oncolytic virus–based cancer immunotherapy. Marketed as Recombinant Human Adenovirus Type 5 Injection, Oncorine became the first oncolytic virus approved for cancer treatment by the Chinese State Food and Drug Administration (CFDA) in November 2005. Since its introduction, it has demonstrated a favorable safety profile and notable antitumor activity across various cancers and malignant pleural effusions. Exploratory clinical studies have also evaluated Oncorine for treating liver cancers, pancreatic cancer, cervical cancer, malignant melanoma, and metastatic liver tumors. Find out more about oncolytic virus cancer drugs @ Oncolytic Virus Analysis A snapshot of the Pipeline Oncolytic Virus Drugs mentioned in the report: Learn more about the emerging oncolytic virus therapies @ Oncolytic Virus Clinical Trials Recent Developments in Oncolytic Virus Treatment Space In November 2025, Imugene Ltd and JW Therapeutics announced a co-development collaboration to evaluate the combination of Imugene's oncolytic virus CF33-CD19 (onCARlytics) and JW's Carteyva®, a CD19-directed autologous CAR-T cell therapy, for patients with advanced solid tumors. This collaboration includes preclinical in vitro and in vivo studies, followed by a Phase I investigator-initiated trial to be conducted exclusively in China at premier CAR-T clinical centers. The approach utilizes Imugene's CF33-CD19 virus to induce CD19 expression on tumor cells, rendering them susceptible to targeting by CD19 CAR-T therapies, a transformative "mark and kill" strategy. In July 2025, Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for CLD-201 (SuperNova), the company's allogeneic adipose stem-cell loaded oncolytic virus for the treatment of soft tissue sarcoma. In June 2025, Oncolytics Biotech presented a poster demonstrating the role of pelareorep in activating anti-tumor immunity in PDAC. In May 2025, Candel Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) had granted Regenerative Medicine Advanced Therapy (RMAT) designation to CAN-2409 (aglatimagene besadenovec), the Company's biological immunotherapy lead candidate, for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease. CAN-2409 was also previously granted FDA Fast Track designation for the same indication. In May 2025, Elicera Therapeutics AB announced that it had entered into a Material Transfer Agreement (MTA) with University Hospital Tübingen in Germany. Under the agreement, the company's oncolytic virus candidates ELC-100 and ELC-201 will be included in tests aimed at developing a new type of companion diagnostic to predict the potential success of a novel neuroendocrine neoplasm (NEN) therapy, immuno-virotherapy. In April 2025, Hangzhou ConVerd Co., Ltd. announced that the first Phase IIa clinical study of hV01, ConVerd's first oncolytic vaccinia virus product, had successfully completed first patient dosing, with the subject in good condition. This phase IIa clinical study investigates the administration of a single dose of recombinant human IL-21 oncolytic poxvirus injection (hV01) per cycle for the treatment of patients diagnosed with advanced sarcoma and cervical cancer. It is important to note that the indication is for advanced sarcoma and recurrent or metastatic cervical cancer for which there is no standard of care available at this stage of the treatment process, or where standard of care has failed. Scope of the Oncolytic Virus Pipeline Report Coverage: Global Key Oncolytic Virus Companies: Oncolytics Biotech, SillaJen, Candel Therapeutics, Binhui Biopharmaceutical, Oryx GmbH, Oncolys Biopharma, EpicentRx, Theriva Biologics, Lokon Pharma, DNAtrix, Surv BioPharma Inc., Treovir, Immvira Pharma, Virogin Biotech, OrienGene Biotechnology, Apices Soluciones, Vyriad, Transgene, BioEclipse Therapeutics, Imugene, CG Oncology, Istari Oncology, Akamis Bio, Elicera Therapeutics, and others Key Oncolytic Virus Pipeline Therapies: Pelareorep, Pexa-Vec, CAN-2409, BS001, ParvOryx, Telomelysin, AdAPT-001, VCN-01, LOAd 703, DNX-2401, Surv.m-CRA-1, G207, MVR-T3011, VG161, OrienX010, AloCelyvir, Voyager-V1, TG6002, CRX-100, CF33-hNIS, CG0070, PVS-RIPO, NG-350A, ELC-201, and others Dive deep into rich insights for new oncolytic Virus treatments, visit @ Oncolytic Virus Drugs Table of Contents Related Reports Oncolytic Virus Therapies Market Oncolytic Virus Therapies Market Size, Target Population, Competitive Landscape, and Market Forecast – 2034 report deliver an in-depth understanding of the market trends, market drivers, market barriers, and key oncolytic virus therapies companies including Targovax, Genelux, Imugene, EpicentRx, Replimune, Genelux Corporation, Candel Therapeutics, DNAtrix, SillaJen, Treovir, Lokon Pharma AB, Istari Oncology, CG Oncology, Amgen, Daiichi Sankyo, and others. Melanoma Market Melanoma Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key melanoma companies including IO Biotech, Merck Sharp & Dohme, Eisai, Regeneron Pharmaceuticals, Iovance Biotherapeutics, Highlight Therapeutics, Linnaeus Therapeutics, Spring Bank Pharmaceuticals, Taiga Biotechnologies, Inc., Aivita Biomedical, Inc., Genentech, Inc., Dana-Farber Cancer Institute, BioMed Valley Discoveries, Inc, Amgen, Checkmate Pharmaceuticals, Astellas Pharma Inc, Galectin Therapeutics Inc., Eucure (Beijing) Biopharma Co., Ltd, Mologen AG, Ultimovacs ASA, Seagen Inc., MedImmune LLC, OnKure, Inc., Syntrix Biosystems, Inc., Anaveon AG, iOx Therapeutics, Portage Biotech, ModernaTX, Inc., Nektar Therapeutics, BioNTech SE, Sapience Therapeutics, HUYABIO International, LLC., Provectus Biopharmaceuticals, Inc., Cantargia AB, Turnstone Biologics, Corp., Aura Biosciences, F-star Therapeutics, Inc., Day One Biopharmaceuticals, Inc., Kinnate Biopharma, Xencor, Inc., HiFiBiO Therapeutics, and others. Colorectal Cancer Market Colorectal Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key colorectal cancer companies, including Mirati Therapeutics, Exelixis, Enterome, Arcus Biosciences, Lyell Immunopharma, AstraZeneca, Novartis Pharmaceuticals, Surgimab, Numab Therapeutics, SOTIO Biotech, Amgen, Sichuan Baili Pharmaceutical, Qilu Pharmaceutical, Bristol-Myers Squibb, NGM Biopharmaceuticals, Takeda, PureTech, Pfizer, Kezar Life Sciences, Salubris, Biotherapeutics , and others. Pancreatic Cancer Market Pancreatic Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key pancreatic cancer companies including FibroGen, OSE Immunotherapeutics, Lokon Pharma, Oncotelic Inc., Tesaro, Inc., Helix BioPharma Corporation, Theradex, Tvardi Therapeutics, Incorporated, AIM ImmunoTech Inc., BioNTech SE, Prestige Biopharma Limited, HCW Biologics, Cantex Pharmaceuticals, XBiotech, Inc., Lumicell, Inc., CARsgen Therapeutics Co., Ltd., Panbela Therapeutics, Inc. , and others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP 21% more press release views with Request a Demo

肺癌 1. SAMHD1 drives immunosuppression in non-small cell lung cancer by promoting macrophage infiltration and restricting oncolytic adenovirus replication. SAMHD1通过促进巨噬细胞浸润驱动非小细胞肺癌免疫抑制。多数NSCLC患者对免疫检查点抑制剂耐药，其背后的微环境机制亟待阐明。研究发现SAMHD1通过DUSP6-ERK1/2通路招募巨噬细胞，且能限制溶瘤腺病毒复制。利用工程化溶瘤病毒降解SAMHD1可逆转免疫抑制，为提高肺癌免疫治疗疗效提供了新靶点。 非小细胞肺癌 | 免疫耐药, SAMHD1 | 溶瘤病毒疗法, 免疫检查点抑制剂 Hu Shichuan · … · Zhao Jing · Journal for immunotherapy of cancer · 2026/01/28 原文链接：https://doi.org/10.1136/jitc-2025-013550 乳腺癌 1. DUSP22 dephosphorylates LGALS1 to enhance T cell-driven antitumor immunity. DUSP22通过去磷酸化LGALS1增强T细胞介导的抗肿瘤免疫。CD8+ T细胞浸润不足限制了乳腺癌免疫治疗效果，需寻找关键调节因子。研究通过转座子筛选发现DUSP22能降解免疫抑制蛋白LGALS1，从而促进T细胞浸润。该研究揭示了DUSP22-LGALS1轴在重塑肿瘤微环境中的作用，为克服免疫检查点阻断耐药提供了新策略。 乳腺癌 | 免疫抑制, DUSP22-LGALS1轴 | 免疫治疗增敏, 转座子筛选 Wang Lijian · … · Miao Kai · Journal for immunotherapy of cancer · 2026/01/28 原文链接：https://doi.org/10.1136/jitc-2025-013142 血液肿瘤 1. Metformin induces ferroptosis associated with lipidomic remodeling in AML. 二甲双胍通过脂质组重塑诱导急性髓系白血病细胞铁死亡。AML高度依赖氧化磷酸化，寻找安全的代谢靶向药物至关重要。研究发现二甲双胍能诱导AML细胞产生活性氧并触发铁死亡，且与DGAT1抑制剂具有协同抗肿瘤作用。该研究为AML的个性化代谢治疗提供了新策略。 急性髓系白血病 (AML) | 铁死亡, 氧化磷酸化, DGAT1 | 脂质组学, 蛋白质组学 Sternadt Dominique · … · Schuringa Jan Jacob · · 2026/02/10 该研究由格罗宁根大学实验血液学专家Jan Jacob Schuringa团队完成 Blood advances 原文链接：https://doi.org/10.1182/bloodadvances.2025016155 2. UBE2O as a key regulator of drug-induced erythropoiesis in the context of myelodysplastic syndromes. UBE2O是骨髓增生异常综合征中药物诱导红细胞生成的关键调节因子。MDS的主要特征是无效造血导致的贫血，现有药物对部分患者疗效有限。研究证实GATA1通过结合UBE2O启动子调节其表达，进而影响晚期红细胞分化过程中的蛋白质组重塑。该研究为改善MDS贫血提供了潜在的治疗新靶点。 骨髓增生异常综合征 (MDS), 无效造血 | UBE2O, GATA1 | 染色质免疫共沉淀 (ChIP), 生物信息学分析 Maffeo Beatrice · … · Cilloni Daniela · Blood advances · 2026/02/10 原文链接：https://doi.org/10.1182/bloodadvances.2025017340 3. Outcomes for CART as 2L vs 3L vs 4L or beyond in aggressive B-cell lymphoma: real-world evidence from the ABC Consortium. 不同治疗线序下CAR-T治疗侵袭性B细胞淋巴瘤的真实世界疗效分析。研究旨在验证CAR-T疗法在不同治疗阶段对复发难治性大B细胞淋巴瘤的实际获益。分析显示2线与3线治疗的生存结果相似，但4线及以后效果较差，且双/三打击淋巴瘤更应尽早使用。该结果为临床优化CAR-T治疗时机提供了重要依据。 大B细胞淋巴瘤 (LBCL) | CD19靶向 | CAR-T细胞疗法, 真实世界研究 Wang John S · … · Karmali Reem · Blood advances · 2026/02/10 原文链接：https://doi.org/10.1182/bloodadvances.2025017120 4. Vulnerability of SRSF2-mutated chronic myelomonocytic leukemia to perturbation of the cGAS-STING pathway. SRSF2突变的慢性粒单核细胞白血病对cGAS-STING通路干扰具有脆弱性。CMML具有向AML转化的风险，亟需能模拟其临床特征的动物模型。研究利用SRSF2突变斑马鱼模型发现，剪接异常会激活cGAS-STING炎症通路并促进白血病表型。抑制该通路可显著缓解病情，为CMML治疗提供了新方向。 慢性粒单核细胞白血病 (CMML) | cGAS-STING通路, SRSF2突变 | 斑马鱼模型, 转录组学 Chen Yanan · … · Sun Xuan · Blood advances · 2026/02/10 原文链接：https://doi.org/10.1182/bloodadvances.2025017005 5. Diabetes mellitus and diabetes-related complications are common in patients with myelodysplastic syndromes but Hemoglobin A1C is an inadequate marker. 糖尿病在MDS患者中常见但糖化血红蛋白并非理想的监测指标。研究关注骨髓增生异常综合征（MDS）患者中糖尿病及其并发症的普遍性。虽然具体摘要内容缺失，但标题指出HbA1c在这一特定人群中存在局限性。该研究提示在血液病背景下需要更准确的代谢评估手段。 骨髓增生异常综合征 (MDS), 糖尿病 | 糖代谢异常 | 糖化血红蛋白 (HbA1c) 检测 Israel Ariel · … · Merzon Eugene · Haematologica · 2026/01/29 原文链接：https://doi.org/10.3324/haematol.2025.300022 6. Blinatumomab-induced remission of refractory immune thrombocytopenia in pediatric acute lymphoblastic leukemia: a case report. 博纳吐单抗诱导小儿急性淋巴细胞白血病中难治性免疫性血小板减少症缓解。该病例报告探讨了在ALL治疗过程中出现的难治性ITP的应对策略。研究发现使用双特异性抗体博纳吐单抗不仅针对白血病，还能有效诱导免疫相关并发症的缓解。这为临床处理复杂的血液肿瘤免疫并发症提供了参考。 急性淋巴细胞白血病 (ALL), 免疫性血小板减少症 (ITP) | CD19/CD3 双特异性抗体 | 博纳吐单抗 (Blinatumomab) Ao Yaning · … · Fu Ying · Haematologica · 2026/01/29 原文链接：https://doi.org/10.3324/haematol.2025.288558 7. GVHD and GRFS in patients with acute myeloid leukemia undergoing allogeneic HCT with treosulfan- versus reduced-intensity busulfan-based conditioning: a subgroup analysis of a randomized phase 3 trial. 替舒凡对比白消安预处理对AML患者异基因造血干细胞移植预后的影响。移植物抗宿主病（GVHD）是alloHCT后的主要并发症，优化预处理方案至关重要。这项3期临床试验分析显示，替舒凡组在无事件生存率和总生存率上均优于白消安组，且慢性GVHD发生率更低。该研究支持替舒凡作为AML移植预处理的更优选择。 急性髓系白血病 (AML), 移植物抗宿主病 (GVHD) | 预处理方案 | 异基因造血干细胞移植 (alloHCT), 替舒凡 Stölzel Friedrich · … · Bethge Wolfgang · Haematologica · 2026/01/29 原文链接：https://doi.org/10.3324/haematol.2025.288770 8. Clonal hematopoiesis driver mutations: molecular mechanisms and clinical implications - inclusive fitness of pre-leukemic hematopoietic stem and progenitor cells through pro-inflammatory features of their progeny. 克隆性造血驱动突变的分子机制及其临床意义综述。研究探讨了携带体细胞突变的造血干祖细胞（HSPCs）如何在长期竞争中持续存在。文章提出“包含适应度”视角，认为突变细胞通过其分化后代产生的促炎微环境来抑制野生型细胞。这种自我维持的反馈回路揭示了克隆动态演变及系统性疾病风险的根源。 克隆性造血 (CH) | 促炎微环境, 包含适应度 | 分子机制综述 Bachrach Tal · … · Shlush Liran I · · 2026/01/29 该研究由魏茨曼科学研究所克隆造血领域专家Liran I Shlush团队完成 Haematologica 原文链接：https://doi.org/10.3324/haematol.2025.287480 9. Would you, could you drive CARs to point-of-care manufacturing? Yes, you should! 推动CAR-T细胞疗法向床旁制造模式转化的观点评述。CAR-T疗法的广泛应用受限于复杂的集中式生产流程和高昂成本。文章探讨了在医疗机构现场进行床旁制造（Point-of-Care）的可行性与必要性。该模式有望缩短制备周期并提高治疗的可及性，是未来细胞免疫治疗的重要发展方向。 细胞免疫治疗可及性 | CAR-T细胞 | 床旁制造 (Point-of-Care) Hankey Kim G · Rapoport Aaron P · Haematologica · 2026/01/29 原文链接：https://doi.org/10.3324/haematol.2025.300339 10. Hypomethylating agents plus venetoclax versus intensive chemotherapy in acute myeloid leukemia with chromosome 5 and 7 abnormalities. HMA联合维奈克拉对比强化化疗治疗伴5/7号染色体异常的AML。5/7号染色体异常的AML预后极差，且缺乏一线治疗方案的对比数据。这项回顾性研究发现，HMA+Ven与强化化疗在缓解率和总生存期上无显著差异。研究强调无论采用何种方案，异基因造血干细胞移植仍是改善长期生存的关键。 急性髓系白血病 (AML), 染色体异常 | BCL-2抑制剂 | 维奈克拉 (Venetoclax), 去甲基化药物 (HMA) Boussi Leora · … · Stahl Maximilian · Haematologica · 2026/01/29 原文链接：https://doi.org/10.3324/haematol.2025.288891 11. Male sex adversely impacts survival and myeloid malignancy risk in MGUS: a real-world population-based study. 男性性别对MGUS患者生存及髓系恶性肿瘤风险具有不利影响。意义未明的单克隆丙种球蛋白病（MGUS）具有向骨髓瘤转化的风险。基于英国大规模人群队列的研究发现，男性患者的5年净生存率显著低于女性。此外，男性发生后续血液恶性肿瘤的比例也更高，提示在临床管理中需关注性别差异。 意义未明的单克隆丙种球蛋白病 (MGUS) | 性别差异 | 流行病学研究, 生存分析 Roman Eve · … · Seymour Frances · Haematologica · 2026/01/29 原文链接：https://doi.org/10.3324/haematol.2025.289200 12. Morphologic and immunophenotypic characterization of lymphocytosis following BCMAtargeted CAR-T cell therapy in relapsed/refractory multiple myeloma. BCMA靶向CAR-T治疗复发难治性多发性骨髓瘤后淋巴细胞增多的特征分析。研究关注CAR-T疗法后患者出现的淋巴细胞增多现象及其临床意义。通过形态学和免疫表型分析，研究旨在区分这种增多是良性反应还是疾病进展。该研究为CAR-T治疗后的疗效评估和并发症监测提供了形态学依据。 多发性骨髓瘤 (MM) | BCMA靶向 | CAR-T细胞疗法, 免疫表型分析 Chai Jiani N · … · Saldarriaga Mateo Mejia · Haematologica · 2026/01/29 原文链接：https://doi.org/10.3324/haematol.2025.289079 13. Frontline ponatinib plus hyper-CVAD over imatinib in adults with Ph-positive acute lymphoblastic leukemia: real-world efficacy and risks of early ponatinib dose reduction. 普纳替尼联合化疗对比伊马替尼治疗费城染色体阳性ALL的真实世界疗效。Ph+ ALL的一线治疗已进入靶向时代，但不同代际TKI的优劣仍需验证。研究比较了普纳替尼与伊马替尼方案的疗效，并探讨了早期减量对风险管理的影响。该研究为优化Ph+ ALL的精准治疗方案提供了真实世界证据。 费城染色体阳性急性淋巴细胞白血病 (Ph+ ALL) | BCR-ABL抑制剂, 普纳替尼 | 真实世界研究, 联合化疗 Yoon Jae-Ho · … · Lee Seok · Haematologica · 2026/01/29 原文链接：https://doi.org/10.3324/haematol.2025.300099 14. Transforming mantle cell lymphoma: the journey across eras. 套细胞淋巴瘤转化治疗的时代演变综述。套细胞淋巴瘤（MCL）的治疗在过去几十年中经历了从传统化疗到靶向及免疫治疗的巨大变革。文章回顾了不同时期的治疗策略及其对患者预后的影响。该综述旨在总结历史经验并展望未来MCL精准治疗的发展方向。 套细胞淋巴瘤 (MCL) | 治疗演变 | 临床综述 Castonguay Mathias · Seymour John F · · 2026/01/29 该研究由著名血液肿瘤学家、澳大利亚勋章获得者John F Seymour团队完成 Haematologica 原文链接：https://doi.org/10.3324/haematol.2025.300275 15. National-level dietary patterns and acute myeloid leukemia: a global ecological analysis. 国家级膳食模式与急性髓系白血病发病率的全球生态学分析。研究旨在探索全球范围内饮食习惯与AML发病风险之间的潜在关联。通过分析不同国家的膳食结构数据与白血病流行病学统计，研究识别了可能影响AML风险的膳食因素。该分析为从公共卫生和营养干预角度预防白血病提供了宏观依据。 急性髓系白血病 (AML), 流行病学 | 膳食模式 | 生态学分析 Wen Diguang · … · National-Level Dietary Patterns And Acute Myeloid Leukemia A Global Ecological Analysis National Natural Science Foundation Of China No · Haematologica · 2026/01/29 原文链接：https://doi.org/10.3324/haematol.2025.288955 16. Lactoferrin reduces febrile neutropenia in children receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled trial. 乳铁蛋白降低接受化疗的血液肿瘤患儿发热性中性粒细胞减少症风险。发热性中性粒细胞减少症是化疗常见的严重并发症，增加感染风险。这项随机安慰剂对照试验发现，补充乳铁蛋白能有效减少患儿发热事件的发生。该研究为改善血液肿瘤患儿化疗期间的支持治疗提供了简单有效的干预手段。 发热性中性粒细胞减少症, 化疗并发症 | 免疫调节 | 乳铁蛋白 (Lactoferrin), 随机对照试验 Decembrino Nunzia · … · Cesaro Simone · Haematologica · 2026/01/29 原文链接：https://doi.org/10.3324/haematol.2025.300007 17. Metabolic syndrome and risk of monoclonal gammopathy of undetermined significance: a large Korean cohort study. 代谢综合征增加意义未明的单克隆丙种球蛋白病风险。代谢综合征（MetS）与多种癌症相关，但其与MGUS的关系尚不明确。这项大规模韩国队列研究发现，MetS显著增加MGUS风险，且风险随代谢组件增加而升高。研究提示通过代谢干预解决MetS可能有助于降低MGUS的发病风险。 意义未明的单克隆丙种球蛋白病 (MGUS), 代谢综合征 | 代谢紊乱 | 队列研究 Lee Ji Yun · … · Bang Soo-Mee · Haematologica · 2026/01/29 原文链接：https://doi.org/10.3324/haematol.2025.300043 18. Myelodysplastic syndrome with cryptic 5q deletions in young male patients showing sustained response to lenalidomide. 伴隐匿性5q缺失的年轻男性MDS患者对来那度胺的持续反应研究。5q缺失是MDS中常见的细胞遗传学异常，通常对来那度胺反应良好。研究报告了在年轻男性患者中发现的隐匿性5q缺失病例，并观察到其对治疗的持久响应。该发现强调了在年轻MDS患者中进行深入细胞遗传学检测的重要性。 骨髓增生异常综合征 (MDS), 5q缺失 | 隐匿性缺失 | 来那度胺 (Lenalidomide), 细胞遗传学检测 Najar Wala · … · Camus Vincent · Haematologica · 2026/01/29 原文链接：https://doi.org/10.3324/haematol.2025.288855 19. Synthetic lethality of decitabine plus ATR inhibition for TP53-mutated AML. 地西他滨联合ATR抑制剂对TP53突变型AML具有合成致死效应。TP53突变导致髓系肿瘤预后极差，且地西他滨单药治疗极易复发。研究发现地西他滨诱导的复制压力在TP53缺失细胞中无法有效解决，联合ATR抑制可诱导有丝分裂灾难。该方案为TP53突变型急性髓系白血病提供了新的治疗方向。 急性髓系白血病 | ATR通路 | 合成致死 Baeten Jeremy T · … · Link Daniel C · · 2026/01/29 该研究由血液肿瘤专家Daniel C Link团队完成 Blood advances 原文链接：https://doi.org/10.1182/bloodadvances.2025018369 20. Pediatric-Inspired Regimens & HSCT for Adolescents & Young Adults with Acute Lymphoblastic Leukemia: Systematic Reviews. 青少年及青年ALL患者治疗方案的系统评价与荟萃分析。AYA人群中急性淋巴细胞白血病（ALL）的最佳一线治疗方案仍存在争议。荟萃分析显示，儿科化疗方案在生存率上优于成人方案，而首次缓解期的造血干细胞移植可能降低生存率。该研究强调了高质量临床试验对优化AYA患者治疗的重要性。 急性淋巴细胞白血病 | 治疗方案优化 | 荟萃分析 Sereda Yuliia · … · Balk Ethan M · Blood advances · 2026/01/29 原文链接：https://doi.org/10.1182/bloodadvances.2025018736 21. Immune biomarkers of increased infection risk in multiple myeloma. 多发性骨髓瘤感染风险的免疫生物标志物获鉴定。感染是多发性骨髓瘤患者发病的主要原因，但目前对免疫功能障碍与感染风险的关联认知有限。通过对1786名患者进行流式细胞术分析，研究确定了CD27+ B细胞等风险因子并构建了免疫评分系统。该研究为通过微创方法监测骨髓瘤患者感染风险提供了临床实用的工具。 多发性骨髓瘤, 感染风险 | CD27+ B细胞, NK细胞 | 下一代流式细胞术, 免疫评分 Zabaleta Aintzane · … · Paiva Bruno · Blood · 2026/01/29 原文链接：https://doi.org/10.1182/blood.2025031744 22. Common variation at 1q23.3, 2p23.3, 2q33.3, and 2p21 influences risk of acute myeloid leukemia. 多中心研究揭示急性髓系白血病新易感位点。急性髓系白血病（AML）具有高度异质性，其遗传易感成分在家族性易感之外仍有待定义。通过对近1.8万例样本的GWAS元分析，研究发现了2p23.3等多个与AML风险及生存显著相关的基因座。这些发现深化了对AML病因学的理解，并证明了疾病亚型特异性风险位点的存在。 急性髓系白血病 (AML) | 2p23.3, EFR3B, POMC | 全基因组关联分析 (GWAS) Ranasinghe Diyanath · … · Allan James M · Blood · 2026/01/29 原文链接：https://doi.org/10.1182/blood.2025031266 23. circPCMTD1: A protein-coding circular RNA that regulates DNA damage response in BCR/ABL1-positive leukemias. 环状RNA编码肽调节白血病DNA损伤修复。环状RNA在白血病中的功能机制尚不完全清楚，特别是其编码蛋白质的能力及其对基因组稳定性的影响。研究发现circPCMTD1编码的cPCMTD1-127aa肽能增强BTR复合物形成，提高白血病细胞对基因组压力的耐受。该研究将circPCMTD1鉴定为BCR/ABL1阳性白血病的潜在治疗靶点。 BCR/ABL1阳性白血病 | circPCMTD1, BTR复合物, DNA损伤反应 | RNA测序, 质谱流式 Papaioannou Dimitrios · … · Garzon Ramiro · Blood · 2026/01/29 原文链接：https://doi.org/10.1182/blood.2025031129 24. Remodelling of the bone marrow vasculature induced by venetoclax and azacitidine damage. 维奈克拉联合阿扎胞苷治疗诱导骨髓血管重塑。Ven/Aza方案广泛用于血液肿瘤，但其对骨髓微环境（BME）的影响此前未被探索。研究发现该疗法会损伤窦状内皮细胞，导致血管渗漏并损害造血干细胞的归巢与植入。该研究强调了维持内皮完整性对于提高供体造血干细胞植入效率的关键作用。 骨髓微环境损伤 | 窦状内皮细胞 (SEC), Bcl2, 造血干细胞归巢 | 转录组学, 活体成像 Ngo Steven · … · Bonnet Dominique · · 2026/01/29 该研究由国际知名干细胞专家、英国皇家医学科学院院士Dominique Bonnet团队完成 Blood 原文链接：https://doi.org/10.1182/blood.2025030055 25. Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape. 双靶点T细胞免疫疗法应对多发性骨髓瘤耐药。单靶点免疫疗法虽改善了骨髓瘤预后，但肿瘤异质性和抗原逃逸仍导致患者最终复发。本文综述了同时针对BCMA和GPRC5D等双靶点的双特异性抗体及CAR-T疗法的最新临床进展。双靶点策略有望通过解决靶点表达异质性来提高疗效，是未来骨髓瘤治疗的重要方向。 复发难治性多发性骨髓瘤 | BCMA, GPRC5D, 抗原逃逸 | 双特异性抗体, CAR-T细胞疗法 van de Donk Niels W C J · … · Einsele Hermann · Blood · 2026/01/29 原文链接：https://doi.org/10.1182/blood.2025032536 消化肿瘤 1. The origin of hepatocellular carcinoma depends on metabolic zonation. 肝细胞癌的起源取决于肝脏的代谢分区。由于难以追踪原生环境中的癌前细胞，癌症的起源一直不甚明确。研究通过小鼠模型发现，Ctnnb1/Arid2突变驱动的癌症更易起源于代谢3区，且Gstm2/3通过抑制铁死亡促进肿瘤发生。该研究揭示了癌症发展的空间代谢决定因素及潜在漏洞。 肝细胞癌 (HCC) | 代谢分区, 铁死亡, Gstm2/3 | 嵌合突变小鼠模型 Guo Jason · … · Zhu Hao · Science (New York, N.Y.) · 2026/01/29 ⭐ 该研究由德克萨斯大学西南医学中心知名肿瘤学专家Hao Zhu团队完成 原文链接：https://doi.org/10.1126/science.adv7129 2. Inulin-Based Oral Chemotherapy Modulates Gut Microbiota and Immune Microenvironment through Inhibition of Neutrophil Extracellular Trap Formation for Improving Cancer Therapy. 菊粉基口服化疗微球通过调节肠道菌群和免疫环境改善癌症治疗。化疗耐药常与肠道菌群失调和中性粒细胞胞外陷阱（NETs）形成有关。研究开发了响应pH释放的菊粉微球，能增加肿瘤局部药物浓度并重塑益生菌群。该系统不仅抑制肿瘤转移，还增强了免疫治疗效果，具有广泛应用前景。 结直肠癌 | 肠道菌群调节 | 口服微球递送 Li Zhenhao · … · Hu Yanfeng · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026/01/29 原文链接：https://doi.org/10.1002/advs.202514318 3. A Patient-Derived Organ-on-Chip Platform for Modeling the Tumor Microenvironment and Drug Responses in Pancreatic Cancer. 用于模拟胰腺癌肿瘤微环境和药物反应的患者来源器官芯片平台。胰腺导管腺癌预后极差，亟需能模拟复杂微环境的精准医学模型。研究将患者来源类器官（PDO）与基质细胞、免疫细胞整合至微流控芯片中。该平台成功模拟了体内肿瘤-基质相互作用，为评估免疫疗效提供了新系统。 胰腺癌 | 肿瘤微环境 | 器官芯片 Adnan Darbaz · … · Bishehsari Faraz · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026/01/29 原文链接：https://doi.org/10.1002/advs.202508934 4. Discovery of Tertiary Benzenesulfonanilide Chemotypes as HDAC Inhibitors via Multistrategy In Silico and Biological Evaluation for Colon Cancer Therapy. 新型HDAC6抑制剂助力结肠癌治疗。组蛋白去乙酰化酶（HDAC）抑制剂是极具潜力的抗癌策略，但亟需开发具有新型化学结构的先导化合物。本研究通过计算模拟和生物评估发现高活性化合物HIT211504993，其能通过调节Myc和Wnt通路显著抑制结肠癌生长。该研究为开发下一代苯磺酰苯胺类HDAC抑制剂提供了理论基础。 结肠癌 | HDAC6, Myc, Wnt/β-catenin通路 | 计算机辅助药物设计, 异种移植模型 Gao Denghui · … · Huang Yanxin · Journal of medicinal chemistry · 2026/01/29 原文链接：https://doi.org/10.1021/acs.jmedchem.5c03634 5. Recent Advances in the Management of Pancreatic Neuroendocrine Tumors: From Diagnosis, Treatment to Biology. 胰腺神经内分泌肿瘤诊疗与生物学研究取得新进展。该类肿瘤异质性强且缺乏高灵敏生物标志物，临床管理面临巨大挑战。综述系统总结了液体活检、影像组学及分子分型在早期诊断、风险分层与个体化治疗中的应用。该综述为提升胰腺神经内分泌肿瘤的精准诊疗水平并克服耐药提供了重要参考。 胰腺神经内分泌肿瘤 | 肿瘤异质性, 分子分型 | 液体活检, 影像组学 Dai Senjie · … · Ji Shunrong · Cancer letters · 2026/01/27 原文链接：https://doi.org/10.1016/j.canlet.2026.218285 6. PD-L1 expression on circulating tumor cells for predicting clinical outcomes in patients with hepatocellular carcinoma receiving PD-(L)1 blockade and targeted therapy. 循环肿瘤细胞PD-L1表达预测肝细胞癌免疫治疗预后。晚期肝癌免疫联合治疗缺乏有效的预测性生物标志物。研究利用端粒酶逆转录酶法检测CTC，发现PD-L1高表达的CTC与患者更短的无进展生存期和总生存期显著相关。该研究证实了PD-L1+ CTC作为无创监测工具在评估肝癌免疫治疗疗效中的临床价值。 肝细胞癌 | 免疫治疗预后, PD-L1 | 循环肿瘤细胞检测 (CTC) Gong Caifeng · … · Zhang Wen · Journal for immunotherapy of cancer · 2026/01/28 原文链接：https://doi.org/10.1136/jitc-2025-013381 7. Oncolytic peptide LTX-315 targets PD-L1 to improve antitumor immune response of nanosecond pulse electric field in liver cancer. 溶瘤肽LTX-315协同脉冲电场增强肝癌抗肿瘤免疫。纳米秒脉冲电场（nsPEF）消融效果短暂，且会诱导PD-L1表达导致T细胞功能障碍。研究发现LTX-315能降低nsPEF诱导的PD-L1水平，并促进树突状细胞活化与免疫记忆形成。该联合策略实现了持久的肿瘤控制，为肝癌介入免疫治疗提供了新思路。 肝癌 | 免疫逃逸, PD-L1 | 溶瘤肽, 纳米秒脉冲电场 (nsPEF) Ji Kun · … · Xiong Bin · Journal for immunotherapy of cancer · 2026/01/28 原文链接：https://doi.org/10.1136/jitc-2025-012438 8. Partial-EMT in oral squamous cell carcinoma: molecular circuitry and clinical translation. 部分上皮-间充质转化驱动口腔癌侵袭转移。口腔鳞状细胞癌具有高侵袭性和高死亡率，其分子调控机制亟待深入探讨。本综述阐述了部分EMT状态如何通过改变肿瘤微环境和增强细胞塑性来促进癌症进展。针对该状态的治疗策略有望成为提高患者生存质量的新方向。 口腔鳞状细胞癌 | 部分EMT, 肿瘤微环境 | 多组学分析 Wang Chunhua · … · Kudo Yasusei · · 2026/01/30 该研究由德岛大学口腔生物科学专家Yasusei Kudo团队完成。 International journal of oral science 原文链接：https://doi.org/10.1038/s41368-025-00417-0 妇科肿瘤 1. Maintenance of PARP Inhibitor Rechallenge Plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor. PARPi联合贝伐珠单抗治疗复发性卵巢癌。对于既往接受过PARP抑制剂的铂敏感复发患者，临床亟需有效的维持治疗方案。II期临床试验显示，尼拉帕利联合贝伐珠单抗使59.1%的患者在6个月内无进展，中位PFS达11.5个月。该联合方案展现出良好的疗效与安全性，值得进一步研究。 铂敏感复发性卵巢癌 | PARP抑制剂, 血管生成抑制 | 尼拉帕利, 贝伐珠单抗, II期临床试验 Cho Hyun-Woong · … · Lee Jung-Yun · Clinical cancer research : an official journal of the American Association for Cancer Research · 2026/01/29 原文链接：https://doi.org/10.1158/1078-0432.CCR-25-2916 2. Cervical Cancer Incidence and Mortality Trends in China: The role of Screening. 中国宫颈癌筛查覆盖率提升显著缓解发病与死亡趋势。尽管开展了多年筛查，中国宫颈癌负担仍重，筛查的群体水平影响亟待评估。研究分析2004-2018年数据发现，高筛查覆盖率与35-44岁女性发病率增速放缓及死亡率稳定强相关。研究强调扩大农村筛查覆盖面并提升质量是实现宫颈癌控制目标的关键。 宫颈癌 | 筛查覆盖率 | 流行病学趋势分析, Joinpoint回归 Yuan Meiwen · … · Zhao Fanghui · · 2026/01/27 该研究由国家癌症中心/中国医学科学院肿瘤医院流行病学专家赵方辉教授团队完成 Cancer letters 原文链接：https://doi.org/10.1016/j.canlet.2026.218286 神经肿瘤 1. Mitochondrial protein carboxyl-terminal alanine-threonine tailing promotes human glioblastoma growth by regulating mitochondrial function. 线粒体蛋白C端AT尾随修饰促进人胶质母细胞瘤生长。癌细胞的高增殖率增加了翻译错误的风险，核糖体相关质量控制（RQC）在其中发挥关键作用。研究发现胶质母细胞瘤干细胞中普遍存在线粒体应激诱导的CAT尾随修饰，该修饰通过增强线粒体电位抑制细胞凋亡。阻断该通路可有效抑制肿瘤细胞过度生长，为GBM治疗提供了新靶点。 胶质母细胞瘤 (GBM) | CAT-tailing, 线粒体功能, RQC通路 | 基因干预, 药理学阻断 Zhang Bei · … · Wu Zhihao · eLife · 2026/01/29 原文链接：https://doi.org/10.7554/eLife.99438 2. Systemic immune correlates of long-term survival after Delta-24-RGD based on the Therapeutic Adenovirus for Recurrent Glioblastoma Effect Trial (TARGET). 溶瘤病毒联合干扰素治疗胶质瘤的免疫关联。增强免疫反应是提高Delta-24-RGD溶瘤病毒疗效的关键策略。1b期试验发现，治疗后循环抗腺病毒IgG和CD8+ NKT样细胞水平可区分长期生存者。免疫适应性指标可作为评估系统性免疫反应及预测生存获益的早期替代标志物。 复发性高级别胶质瘤 | 溶瘤病毒, 干扰素-γ, CD8+ NKT样细胞 | Delta-24-RGD, 单细胞RNA测序 Ene Chibawanye I · … · Lang Frederick F · · 2026/01/29 该研究由MD安德森癌症中心神经外科主任Frederick F Lang团队完成 Clinical cancer research : an official journal of the American Association for Cancer Research 原文链接：https://doi.org/10.1158/1078-0432.CCR-25-3566 3. Brain-Resident MAIT Cells Infiltrate GL261 Tumors, and Activated MAIT Cell Signatures Are Associated With Improved Outcomes in Glioma. 脑驻留MAIT细胞具有抗胶质瘤保护作用。MAIT细胞在脑部及胶质瘤免疫中的表型和作用尚不明确，限制了相关免疫疗法的发展。研究发现活化的MAIT细胞特征与胶质瘤患者生存率正相关，且在小鼠模型中证实其缺失会缩短生存期。该发现揭示了MAIT细胞在CNS免疫监视中的潜力，为胶质瘤免疫治疗提供了新靶点。 胶质瘤 | MAIT细胞, IL-17, IFN-γ | 流式细胞术, 转录组分析 Eddy Eleanor M · … · Corbett Alexandra J · Neurology(R) neuroimmunology & neuroinflammation · 2026/01/29 原文链接：https://doi.org/10.1212/NXI.0000000000200546 罕见癌种 1. METTL3/CD98-mediated glutamate efflux in CAFs drives CD8+ T cell exhaustion and impedes neoadjuvant immunochemotherapy. METTL3/CD98介导的谷氨酸外流驱动T细胞耗竭。神经递质在抑制抗肿瘤免疫中的作用日益受到关注，但其在免疫化疗中的作用不明。研究发现头颈鳞癌中成纤维细胞通过METTL3/m6A轴促进谷氨酸分泌，诱导CD8+ T细胞耗竭。耗竭谷氨酸可显著增强新辅助免疫化疗的疗效。 头颈部鳞状细胞癌(HNSCC) | METTL3, 谷氨酸外流, CD8+ T细胞耗竭 | 新辅助免疫化疗, m6A测序 Feng Chunyu · … · Shang Zhengjun · · 2026/01/28 该研究由武汉大学口腔肿瘤专家尚政军团队完成 Cell reports 原文链接：https://doi.org/10.1016/j.celrep.2026.116933 2. The FOXC2-LAMA4 Axis Orchestrates Vasculogenic Mimicry and Immunosuppressive Niche Formation to Drive Metastatic Cascade in Renal Cell Carcinoma. FOXC2-LAMA4轴通过血管拟态和免疫抑制生态位驱动肾癌转移。晚期透明细胞肾细胞癌的侵袭性转移源于肿瘤内部的异质性。研究通过单细胞和空间组学发现FOXC2+亚群通过激活LAMA4重塑肺转移生态位。该成果确立了靶向FOXC2-LAMA4轴在阻断肾癌转移中的治疗潜力。 肾透明细胞癌 | 血管拟态 | 空间多组学 Yao Jiaxi · … · Liu Tao · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026/01/29 原文链接：https://doi.org/10.1002/advs.202516382 3. Olutasidenib in recurrent/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b/2 trial. Olutasidenib治疗IDH1突变软骨肉瘤的临床疗效。软骨肉瘤是一种缺乏有效治疗手段的罕见肿瘤，其中约65%携带IDH1/2突变。这项1b/2期临床试验评估了IDH1抑制剂Olutasidenib的安全性，结果显示其在常规软骨肉瘤患者中具有良好的耐受性和疾病控制能力。该研究为这种罕见癌症的精准治疗提供了新的临床证据。 软骨肉瘤 | IDH1突变 | 临床试验, 靶向治疗 Jones Robin L · … · Van Tine Brian A · · 2026/01/29 该研究由华盛顿大学圣路易斯分校肉瘤研究专家Brian Van Tine团队完成。 Nature communications 原文链接：https://doi.org/10.1038/s41467-026-68716-6 泛癌种 1. Hematologic complications in patients exposed to poly-ADP ribose polymerase inhibitors. PARP抑制剂暴露患者的血液学并发症研究。PARP抑制剂在多种实体瘤治疗中广泛应用，但其引起的骨髓抑制等血液学毒性不容忽视。研究分析了患者在接受PARP抑制剂治疗后出现的血液学异常及其发生机制。该研究提醒临床医生在应用此类药物时需加强血液学监测与风险防控。 药物毒性, 血液学并发症 | PARP抑制剂 | 临床监测 Cannova Joseph M · … · Drazer Michael W · Haematologica · 2026/01/29 原文链接：https://doi.org/10.3324/haematol.2025.288518 2. PlatinumIV Complex Enabling Multiple and Potent Tumor Microenvironment Remodeling for Cancer Chemo-Immunotherapy. 新型铂(IV)前药协同重塑肿瘤微环境。肿瘤微环境常削弱化疗疗效并抑制免疫原性细胞死亡。该研究开发了整合顺铂与吡非尼酮类似物的前药，通过耗竭谷氨酸和抑制P-gp重塑微环境。该方案成功诱导了强烈的免疫原性细胞死亡，显著提升了抗肿瘤疗效及安全性。 肿瘤化学免疫治疗 | 肿瘤微环境重塑, 免疫原性细胞死亡(ICD) | 铂(IV)配合物, 前药设计 Sun Rensong · … · Wang Lei · · 2026/01/29 该研究由大连理工大学精细化工国家重点实验室Wang Lei团队完成 Journal of medicinal chemistry 原文链接：https://doi.org/10.1021/acs.jmedchem.5c03032 3. Preventing surgery-induced natural killer cell suppression and metastases by inhibiting PI3K-gamma signaling in myeloid-derived suppressor cells. 抑制MDSCs中的PI3K-γ信号预防术后NK细胞抑制与转移。手术诱导的髓系抑制细胞（MDSCs）是术后免疫抑制和癌症转移的主因，但其机制未明。研究通过单细胞测序发现sx-MDSCs中PI3K信号上调，并筛选出PI3K-γ抑制剂可恢复NK细胞活性。该发现为减少术后肿瘤复发和转移提供了极具前景的免疫治疗策略。 癌症转移 | 术后免疫抑制, PI3K-γ信号 | 单细胞RNA测序, 小分子筛选 Angka Leonard · … · Auer Rebecca C · Journal for immunotherapy of cancer · 2026/01/29 原文链接：https://doi.org/10.1136/jitc-2025-013304 4. MMP3 overexpression enhances CAR-T cell infiltration and antitumor activity in a CAF-enriched solid tumor model. 过表达MMP3增强CAR-T细胞在基质丰富实体瘤中的浸润。细胞外基质（ECM）是阻碍CAR-T细胞进入实体瘤的主要物理屏障。研究构建了协同表达基质金属蛋白酶-3（MMP3）的CAR-T细胞，显著提升了其穿透ECM并杀伤肿瘤的能力。该策略在富含成纤维细胞的肿瘤模型中表现优异，为克服实体瘤基质屏障提供了新方案。 实体瘤 | 细胞外基质屏障, MMP3 | CAR-T细胞疗法 Zhu Yuge · … · Zhang Chaoting · Journal for immunotherapy of cancer · 2026/01/28 原文链接：https://doi.org/10.1136/jitc-2025-013211 5. Advancing ICOS agonism in solid tumors: lessons from INDUCE-1. 实体瘤中ICOS激动剂开发的经验与挑战。ICOS是CD28家族中重要的共刺激分子，但在临床试验中表现出的抗肿瘤活性有限。综述分析了INDUCE-1等研究结果，指出ICOS调节依赖于效应与调节性T细胞的时空平衡。该研究强调未来需通过合理的联合用药与生物标志物筛选来释放ICOS通路的治疗潜力。 实体瘤 | 免疫共刺激, ICOS | 免疫激动剂开发 Habibzadeh Parham · Davar Diwakar · Journal for immunotherapy of cancer · 2026/01/29 原文链接：https://doi.org/10.1136/jitc-2025-013991 6. Biological Activity and Structural Biology of Current KAT6A Inhibitor Chemotypes. KAT6A抑制剂的生物活性与结构生物学研究进展。组蛋白乙酰转移酶KAT6A是重要的癌症靶点，但其抑制剂开发曾被认为极具挑战。研究通过生化实验与结构生物学手段，评估了多种KAT6A抑制剂骨架，并报告了新型硫代二嗪类抑制剂。该工作为针对KAT6A的抗肿瘤药物设计提供了详实的药理学与结构基础。 癌症治疗 | 组蛋白乙酰化, KAT6A | 药物设计, 结构生物学 Suwandi Adi · … · Baell Jonathan B · · 2026/01/29 该研究由国际著名药物化学家、PAINS概念提出者Jonathan Baell教授团队完成 Journal of medicinal chemistry 原文链接：https://doi.org/10.1021/acs.jmedchem.5c01426 7. Discovery of Novel Orally Bioavailable Polθ Inhibitors with Arylalkyne Scaffolds for Targeting HR-Deficient Cancers. 发现新型口服Polθ抑制剂用于治疗同源重组缺陷型癌症。Polθ是介导微同源末端连接的关键酶，在HR缺陷型肿瘤中过度表达，是极具潜力的治疗靶点。研究开发了具有芳基炔骨架的Polθ抑制剂，展现出纳米级抑制活性及优异的口服生物利用度。该化合物在异种移植模型中显著抑制肿瘤生长，为HR缺陷型癌症提供了新型候选药物。 同源重组缺陷 (HRD) | DNA修复, Polθ | 药物研发, 口服生物利用度 Zhang Jinyang · … · Zhu Qihua · Journal of medicinal chemistry · 2026/01/29 原文链接：https://doi.org/10.1021/acs.jmedchem.5c01977 声明：本文使用了AI进行翻译和总结